Ocular manifestation of GVHD is among the most challenging to treat, often leading to chronic inflammation and corneal tissue ...

The FDA has approved Incyte's axatilimab as a treatment for chronic graft-versus-host disease (GvHD), making it a companion to the company's Jakafi for the disorder. The US regulator has cleared ...

Itolizumab's potential as a first-line treatment for acute GVHD is highlighted by reduced mortality and improved outcomes. Although itolizumab did not improve response rates at Day 29 for patients ...

The GVHD Treatment Market focuses on pharmaceuticals and therapies aimed at managing or preventing this condition. The expansion of transplant centers is not limited to established healthcare ...

Most activating or suppressing T-cell-co-stimulatory molecules have been shown to influence the phenotype of GVHD. Activating receptors would be logical targets for the treatment or prevention of ...

The trial involves a one-time infusion of the cell therapy to treat subjects undergoing haploidentical ... a matched donor while also minimising GvHD risks. The drug is an off-the-shelf engineered ...

The patients had chronic GVHD symptoms despite prior treatment with at least two lines of systemic therapy. Current options are steroids and immunosuppressant drugs like cyclosporine, as well as ...

Allogeneic hematopoietic stem cell transplantation (HSCT) is an important and potentially curative treatment of haematological malignancies, but GvHD and infections affect outcomes. We present ...

Kiji Therapeutics engineered MSCs + IL-10 and CXCR4 offer tighter targeting and greater potency for challenging inflammatory diseases.

High Treatment Costs High treatment costs represent one of the most significant barriers in the GVHD treatment market, as patients face substantial financial challenges. The expenses associated with ...